The Cooper Companies key statistics and ratios
In fiscal 2025, The Cooper Companies had return on equity of 4.6%, an operating margin of 16.7%, debt equal to 30.4% of equity and a current ratio of 1.89. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Oct 2009 | 2010Oct 2010 | 2011Oct 2011 | 2012Oct 2012 | 2013Oct 2013 | 2014Oct 2014 | 2015Oct 2015 | 2016Oct 2016 | 2017Oct 2017 | 2018Oct 2018 | 2019Oct 2019 | 2020Oct 2020 | 2021Oct 2021 | 2022Oct 2022 | 2023Oct 2023 | 2024Oct 2024 | 2025Oct 2025 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 55.2% | 58.4% | 60.5% | 63.9% | 64.7% | 63.5% | 59.6% | 59.6% | 63.9% | 64.4% | 66.2% | 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% | 65.9% |
| Operating margin | 13.9% | 16.4% | 17.1% | 19.6% | 19.3% | 17.8% | 13.2% | 16.5% | 20.1% | 15.9% | 20.6% | 12.8% | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% | 12.8% |
| Net margin | 9.3% | 9.7% | 13.2% | 17.2% | 18.7% | 15.7% | 11.3% | 13.9% | 17.4% | 5.5% | 17.6% | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% | 13.5% |
| Free-cash-flow margin | 12.0% | 16.7% | 17.5% | 14.9% | 15.0% | 12.6% | 8.2% | 18.2% | 21.8% | 18.8% | 15.9% | 7.2% | 17.9% | 13.6% | 6.0% | 7.4% | 10.6% | 16.0% |
| Return on equity | 6.5% | 7.0% | 9.7% | 12.0% | 12.9% | 10.8% | 7.8% | 10.2% | 12.7% | 4.3% | 13.5% | 6.4% | 54.7% | 5.5% | 4.0% | 5.0% | 4.6% | 6.9% |
| Return on assets | 3.9% | 4.4% | 6.8% | 8.9% | 9.7% | 7.1% | 4.6% | 6.1% | 8.0% | 2.6% | 7.5% | 3.7% | 36.0% | 3.7% | 2.5% | 3.3% | 3.0% | 4.5% |
| Asset turnover | 0.42 | 0.46 | 0.52 | 0.52 | 0.52 | 0.45 | 0.40 | 0.44 | 0.46 | 0.46 | 0.43 | 0.37 | 0.36 | 0.31 | 0.31 | 0.33 | 0.33 | 0.34 |
| Current ratio | 2.87 | 2.46 | 2.02 | 2.51 | 2.33 | 1.79 | 1.48 | 1.73 | 2.41 | 2.03 | 1.05 | 1.27 | 2.00 | 1.20 | 1.76 | 1.91 | 1.89 | 1.22 |
| Debt to equity | 50.7% | 36.7% | 20.3% | 17.0% | 14.3% | 53.8% | 50.7% | 57.4% | 36.9% | 61.2% | 50.3% | 46.9% | 21.3% | 38.5% | 34.0% | 32.0% | 30.4% | 30.5% |
| Interest cover (operating income ÷ interest) | 3.4x | 5.2x | 13.1x | 24.1x | 33.4x | 38.5x | 13.1x | 12.4x | 12.8x | 4.9x | 8.0x | 8.5x | 21.9x | 8.9x | 5.1x | 6.2x | 6.8x | 6.1x |
| Effective tax rate | 12.4% | 9.3% | 9.0% | 9.7% | 4.9% | 8.3% | 4.8% | 7.0% | 5.4% | 57.8% | 2.2% | 10.5% | — | 18.8% | 28.7% | 32.6% | 33.8% | −23.3% |
| R&D as % of revenue | 3.1% | 3.0% | 3.3% | 3.6% | 3.7% | 3.9% | 3.9% | 3.3% | 3.2% | 3.3% | 3.3% | 3.8% | 3.2% | 3.3% | 3.8% | 4.0% | 4.2% | 4.0% |
| SG&A as % of revenue | 36.2% | 37.4% | 38.6% | 39.1% | 38.5% | 39.8% | 39.6% | 36.8% | 37.4% | 38.4% | 37.5% | 40.8% | 41.4% | 40.6% | 41.8% | 39.4% | 39.8% | 44.5% |
| Capital spending as % of revenue | 8.7% | 6.4% | 7.8% | 6.9% | 11.2% | 13.9% | 13.5% | 7.8% | 5.9% | 7.6% | 11.0% | 12.8% | 7.3% | 7.3% | 10.9% | 10.8% | 8.9% | 8.4% |
| Free cash flow ÷ net income | 128.5% | 171.9% | 132.6% | 86.7% | 80.3% | 80.3% | 72.7% | 130.3% | 125.1% | 339.7% | 90.2% | 73.9% | 17.8% | 116.7% | 73.1% | 73.4% | 115.7% | 118.9% |
| Dividends ÷ net income | 2.7% | 2.4% | 1.6% | 1.2% | 1.0% | 1.1% | 1.4% | 1.1% | 0.8% | 2.1% | 0.6% | 1.3% | 0.1% | 0.8% | 1.0% | 0.0% | 0.0% | — |
| Dividends and buybacks ÷ free cash flow | 2.1% | 1.4% | 1.2% | 34.4% | 71.6% | 36.3% | 47.5% | 0.8% | 12.4% | 0.6% | 37.8% | 28.8% | 5.3% | 18.1% | 1.4% | 0.0% | 66.9% | 95.0% |
| Quarter | 2024 Q4Oct 2024 | 2025 Q1Jan 2025 | 2025 Q2Apr 2025 | 2025 Q3Jul 2025 | 2025 Q4Oct 2025 | 2026 Q1Jan 2026 | 2026 Q2Apr 2026 | 2026 Q3Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 66.5% | 68.4% | 67.8% | 65.3% | 61.1% | 67.9% | 68.0% | 66.8% |
| Operating margin | 19.5% | 18.9% | 18.4% | 16.6% | 13.2% | 20.8% | −2.9% | 20.8% |
| Net margin | 11.5% | 10.8% | 8.7% | 9.3% | 7.9% | 12.8% | −7.2% | 40.6% |
| Free-cash-flow margin | 12.6% | 10.5% | 1.8% | 15.5% | 14.1% | 15.5% | 8.9% | 25.6% |
| Current ratio | 1.91 | 1.99 | 2.10 | 2.12 | 1.89 | 1.34 | 1.27 | 1.22 |
| Debt to equity | 31.9% | 31.2% | 31.2% | 29.6% | 30.4% | 29.9% | 29.8% | 30.5% |
| R&D as % of revenue | 3.7% | 4.2% | 4.5% | 4.2% | 3.9% | 4.3% | 3.9% | 3.9% |
| SG&A as % of revenue | 38.4% | 40.2% | 39.8% | 39.8% | 39.4% | 38.1% | 62.5% | 37.6% |
Financial health
- Short-term assets cover short-term liabilities $2.3bn of assets due within a year against $1.9bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $2.3bn short-term assets against $2.5bn of longer-dated liabilities.
- More cash than debt $155m of cash against $2.5bn of debt.
- Debt below 40% of shareholders' equity Debt is 31% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 34% to 31% over five years.
- A year's operating cash flow covers at least 20% of debt $1.0bn of operating cash flow against $2.5bn of debt.
- Operating profit covers interest at least five times over Operating income of $544m against $89m of interest.
Moat
Strong moat
How hard The Cooper Companies's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 8 / 20
Cash operating profit has been a median 7.0% of total assets over 10 years.
- Pricing power 20 / 20
Gross margin has been a median 65.7%, moving by 1.3 percentage points (standard deviation) across 10 years.
- Durability 15 / 20
Operating margin has been a median 16.7%; its worst year was 12.8%.
- Cash conversion 18 / 20
Free cash flow was positive in 10 of 10 years, at a median 16.1% of revenue.
- Discipline 17 / 20
The diluted share count fell 1.5% over five years; stock-based pay has been a median 1.6% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).
Compare with peers
- Align Technology statistics
- Dentsply Sirona Inc. statistics
- West Pharmaceutical Services statistics
- Envista Holdings Corp statistics
- ICU Medical Inc statistics
Head to head: ALGN vs COOCOO vs XRAYCOO vs WST
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies